Design, Synthesis, and Molecular Docking Study of Novel Heterocycles Incorporating 1,3,4-Thiadiazole Moiety as Potential Antimicrobial and Anticancer Agents
作者:Mohamed El-Naggar、Hanan A. Sallam、Safaa S. Shaban、Salwa S. Abdel-Wahab、Abd El-Galil E. Amr、Mohammad E. Azab、Eman S. Nossier、Mohamed A. Al-Omar
DOI:10.3390/molecules24061066
日期:——
A new series of 5-(3,5-dinitrophenyl)-1,3,4-thiadiazole derivatives were prepared and evaluated for their in vitro antimicrobial, antitumor, and DHFR inhibition activity. Compounds 9, 10, 13, and 16 showed strong and broad-spectrum antimicrobial activity comparable to Amoxicillin and Fluconazole as positive antibiotic and antifungal controls, respectively. Compounds 6, 14, and 15 exhibited antitumor
制备了一系列新的 5-(3,5-二硝基苯基)-1,3,4-噻二唑衍生物,并评估了它们的体外抗菌、抗肿瘤和 DHFR 抑制活性。化合物 9、10、13 和 16 分别显示出与阿莫西林和氟康唑作为阳性抗生素和抗真菌对照物相当的强广谱抗菌活性。化合物 6、14 和 15 表现出对四种人类癌细胞系、CCRF-CEM 白血病、HCT-15 结肠、PC-3 前列腺和 UACC-257 黑色素瘤细胞系的抗肿瘤活性,使用多柔比星作为参考药物。与甲氨蝶呤 (IC50 = 0.14 ± 1.38 µM) 相比,化合物 10、13、14 和 15 被证明是活性最强的 DHFR 抑制剂,其 IC50 范围为 0.04 ± 0.82–1.00 ± 0.85 µM。